Anti-Thyroid Drugs Market Report 2026

Anti-Thyroid Drugs Market Overview

• Anti-Thyroid Drugs market size has reached to $2.49 billion in 2025 • Expected to grow to $2.85 billion in 2030 at a compound annual growth rate (CAGR) of 2.9% • Growth Driver: Increasing Prevalence Of Thyroid Cancer Driving Market Growth Due To Rising Need For Effective Therapeutic Interventions • Market Trend: Product Innovation Through Monoclonal Antibody Therapies In The Market • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Anti-Thyroid Drugs Market?

Anti-thyroid drugs refer to agents that function by preventing the manufacture of thyroid hormones or by reducing the action of thyroid hormones. Additionally, they are suggested for use in radioactive iodine uptake tests to assess thyroid function and safeguard the thyroid gland in case of radiation exposure. The main types of anti-thyroid drugs are thionamides (inhibition of hormone synthesis) and iodides (inhibition of hormone release). Ethionamide drugs pharmacologically normalize thyroid hormone levels. The drugs are administered orally, and intravenously, and others are distributed by wholesalers/distributors, retail chains, online distribution, and others.

What Is The Anti-Thyroid Drugs Market Growth Forecast?

The anti-thyroid drugs market size is expected to see steady growth in the next few years. It will grow to $2.85 billion in 2030 at a compound annual growth rate (CAGR) of 2.9%. The growth in the forecast period can be attributed to growth in autoimmune thyroid diseases, improved screening programs, rising healthcare access, innovation in thyroid regulation therapies, aging population. Major trends in the forecast period include rising diagnosis of thyroid disorders, growing use of thionamide-based drugs, expansion of outpatient thyroid management, increased monitoring of hormone levels, improved drug safety profiles.

Global Anti-Thyroid Drugs Market Segmentation

1) By Drug Type: Thionamides (Inhibition Of Hormone Synthesis), Iodides (Inhibition Of Hormone Release) 2) By Route of Administration: Oral, Intravenous, Other Route Of Administration 3) By Distribution Channel: Wholesaler Or Distributors, Retail Chain, Online Distribution, Other Distribution Channels Subsegments: 1) By Thionamides (Inhibition Of Hormone Synthesis): Methimazole, Propylthiouracil 2) By Iodides (Inhibition Of Hormone Release): Potassium Iodide, Lugol's Iodine Solution

What Is The Driver Of The Anti-Thyroid Drugs Market?

The increasing prevalence of thyroid cancer is expected to drive the growth of the anti-thyroid drugs going forward. Thyroid cancer is a disease in the thyroid gland (a gland near the base of the throat that produces hormones to help regulate body temperature, heart rate, blood pressure, and weight). The rising prevalence of thyroid cancer is primarily due to greater exposure to medical radiation and environmental carcinogens. Anti-thyroid drugs help to discover thyroid cancer by providing early detection that can help improve treatment outcomes. For instance, in August 2023, according to the American Society of Clinical Oncology, a US-based community for oncologists and surgeons, in the United States, an estimated 43,720 adults (12,540 men and 31,180 women) were diagnosed with thyroid cancer in 2023, and an estimated 2,120 deaths (970 men and 1,150 women) from this disease were expected to occur in the same year. Therefore, the increasing prevalence of thyroid cancer is propelling the growth of the anti-thyroid drugs industry.

Key Players In The Global Anti-Thyroid Drugs Market

Major companies operating in the anti-thyroid drugs market are Mylan N.V., Abbott Laboratories, GlaxoSmithKline plc, Merck & Co., Pfizer Inc., Allergan plc, RLC LABS Inc., Lannett Company Inc., Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Ltd., Alkem Laboratories Ltd., Akorn Inc.

Global Anti-Thyroid Drugs Market Trends and Insights

Major companies operating in the anti-thyroid drugs market are focusing on innovating products, such as monoclonal antibodies, to improve patient outcomes, reduce adverse effects, and strengthen their competitive position. Monoclonal antibodies refer to laboratory-engineered proteins that precisely target specific molecules in the body to help treat diseases more effectively. For instance, in March 2025, Innovent Biologics, Inc., a China-based biotechnology company, announced the approval of SYCUME, an anti-IGF-1R monoclonal antibody, by China's National Medical Products Administration (NMPA) for the treatment of thyroid eye disease (TED). SYCUME is the first drug of its kind approved in China and the second worldwide, offering a new, effective treatment option that significantly reduces proptosis and inflammation while improving patients' quality of life. The approval is based on positive clinical trial results demonstrating SYCUME’s ability to address the unmet needs of TED patients, providing a safer, more accessible alternative to existing therapies.

What Are Latest Mergers And Acquisitions In The Anti-Thyroid Drugs Market?

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc, for approximately $27.8 billion. Through this acquisition, Amgen aims to enhance its anti-thyroid drugs portfolio by integrating Horizon Therapeutics’ innovative therapies for thyroid disorders, enabling the development of advanced treatments for patients with hyperthyroidism and other thyroid-related conditions. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company specializing in rare and specialty diseases with a strong track record in developing anti-thyroid drugs and endocrine disorders.

Regional Insights

North America was the largest region in the anti-thyroid drugs market in 2025. The Middle East is expected to be the fastest-growing region in the anti-thyroid drugs market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anti-Thyroid Drugs Market?

The anti-thyroid drugs market consists of sales of levothyroxine, propylthiouracil, and methimazole. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anti-Thyroid Drugs Market Report 2026?

The anti-thyroid drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-thyroid drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.